01The frame shift
The September 2025 joint Enforcement Notice from ASA, MHRA and GPhC did something that almost no commentary picked up at the time: it stopped treating “promotion of a prescription-only medicine to the public” as a question of copy, and started treating it as a question of surface architecture. Regulation 284 of the Human Medicines Regulations 2012 remains the underlying prohibition: no advertisement likely to lead to the use of a prescription only medicine may be published to the public. CAP rule 12.12 remains the operational standard. What changed is what counts as the breach.
Pre-2025, the typical adjudication turned on whether a named POM appeared in public-facing copy. Post-2025, the adjudication routinely turns on whether the funnel as a whole (ad, landing page, intake form, pricing tile, post-consultation portal) induces the public to seek a specific class of medicine. Naming the active is no longer required. A category descriptor (“weight loss jab”, “skinny jab”, “GLP‑1”) plus a numeric price plus a one-tap booking link is, in the regulator’s reading, a promotional instrument.
This is a frame shift, not a tweak. The agency templates that were defensible in 2024 produce upheld rulings in 2026 with the same copy.
02What is now “promotion”
Reading the 2025 ruling cohort in aggregate, six surface patterns now reliably trigger a CAP 12.12 finding:
- Numeric price plus category descriptor in any public-facing surface (ad, organic social, landing-page above-the-fold, pricing card). The doctor headshot does not neutralise it.
- Outcomes language (“up to 20% body weight”, “average 15kg”, “wrinkle-free for six months”) tied to a category that contains only POMs.
- Before / after carousels presenting the visual outcome of the medicine class, even when the asset itself does not name a brand.
- “Subject to consultation” small print placed on the same surface as the inducement; the regulator now reads this as a hedge, not a cure.
- Endorsements and patient stories on the public surface where the patient’s outcome implies the medicine class.
- Funnel-wide repetition of the same numeric price across ad, landing and intake form, even when each surface in isolation would arguably comply.
03What survives
The defensible funnel inverts the relationship between the public surface and the consultation gate. Pricing, brand identifiers, dose comparisons and outcomes language move behind a clinician-led consultation; what remains visible to the public is the consultation itself, the eligibility criteria, and the safety frame.
Six surface patterns that still publish:
- Service-led ads that name the consultation, the eligibility criteria and the regulator-friendly copy ladder, without naming the medicine class.
- Mechanism, not outcome: “a once-weekly injection that mimics a satiety hormone” rather than “lose 20% body weight”.
- Eligibility, not aspiration: the ad sells who the service is licensed for, not what the service achieves.
- Risk-balanced safety frame on the same surface as any clinical claim, sized in proportion to the claim.
- Pricing only after consultation, presented as a clinical fee rather than a per-pen unit price.
- Editorialised before / after: weight, BMI delta or visual outcome shown only as part of a narrative arc that names the consultation, the contraindications and the duration of treatment.
04The bridging wording bank
For brands moving from a 2024-template funnel to a 2026-defensible one, three substitutions do most of the work:
- “Wegovy from £149” → “Clinically assessed weight-management consultation, from £79”. The medicine, if appropriate, is then priced inside the consultation, not on the ad.
- “Lose up to 20% body weight” → “Eligibility for a GLP‑1 receptor agonist programme is assessed against NICE‑aligned criteria.” The aspirational claim becomes an eligibility claim; both are commercially useful, only the second is defensible.
- “Skinny jab” / “weight loss jab” (in a public surface) → remove. There is no defensible substitution for a category descriptor that the regulator now reads as the inducement itself.
None of this is a creative compromise. The strongest commercial copy in this lane was already the consultation-led pattern, because it carries the only thing the prospect can actually buy on the public surface: a clinician’s judgement that the medicine is, or is not, right for them.
05Governance, not just copy
The other change in the 2025 cohort is who the regulator is willing to name. GPhC has now joined the ASA in publishing standards-of-conduct findings against the registered pharmacy and the responsible pharmacist, not just the advertiser. For prescription-led funnels, this means the prescriber’s registration is, in practice, on the surface that the ad sits on. CAP 12.12 compliance is a governance question now, not just a copy question.
The practical consequence is that pre-publication review needs to read the funnel, not just the ad. A claim-risk audit that only looks at the paid-social tile will routinely return GREEN on the asset and BLACK on the funnel. The two findings are different documents.
06Sources
- Enforcement Notice: advertising of prescription-only medicines used for weight management, published jointly by CAP, MHRA and GPhC (23 September 2025)
- MHRA news: regulators unite to reaffirm prescription weight-loss medicine advertising rules (26 September 2025)
- CAP Enforcement Report and consumer research on weight-loss POM advertising (2 April 2026), confirming 18 rulings since 2025
- CAP Code Section 12 (Medicines, medical devices, health-related products and beauty products)
- Human Medicines Regulations 2012, regulation 284 (legislation.gov.uk)
- MHRA Blue Guide on advertising and promoting medicines
- GPhC standards for pharmacy professionals